Fostering innovative solutions for dermatological disorders
Pune based startup , Ahammune Biosciences ' s lead drug candidate has a first-in class mechanism of action for vitiligo and has been developed as a targeted treatment
BY RAHUL KOUL
Dermatological diseases are a major health burden globally . Though not terminal , the change in appearance caused by these diseases has a profound effect on the quality of life of patients , as they have to live with it throughout their life . Associated myths about these diseases have caused ostracization of patients in several sections of the society and have added to their psychological trauma . Treatments are hence being desperately sought .
Pune based Ahammune
Biosciences is working on the innovative solutions for such unmet dermatological disorders . Founded by Dr . Krishnamurthy Natarajan and Dr . ParuI Ganju , Ahammune boasts of an interdisciplinary team of dedicated scientists and thought leaders who share a common goal of translating scientific breakthroughs to foster innovative treatments .
Ahammune ' s lead drug candidate , AB1001 has a first-in class mechanism of action for vitiligo and has been developed as a targeted treatment . Pre-clinical studies with AB1001 have established this molecule as a promising drug candidate . It is not only effective in animal studies but is also very safe when applied for long periods of time . With approvals received from DCGI for our Phase 1 , it has initiated human trials which are currently underway to probe the safety of the drug . This is extremely important for treatments of chronic diseases like vitiligo , where long term interventions are required .
BIOVOICENEWS . COM 17